GUMDROP : WHC - A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer

Created by Nancy Dawson, last modified on Sep 16, 2013
Description:The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.
Link:http://clinicaltrials.gov/ct2/show/NCT01809691
Site:Washington Hospital Center
Principle Investigator:Dr. George Philips, MD